Contact

What's new in the H2020 SME Instrument?


, , , ,
Integral service around a transaction
BY : Diego GutiérrezFebruary Mon, 2018

We explain what the H2020 SME Instrument is, which companies it is aimed at and what is new for the 2018-2020 period. We also present some of the projects benefiting from phase 2 and the distribution of funds.

Get in touch with our experts.

What is the H2020 SME Instrument?

The H2020 SME Instrument is a business growth programme aimed at supporting European SMEs aiming to become international leaders in their niche markets.

This programme offers a grant, at 70% intensity, of €50,000 in phase 1 and up to €2.5M in phase 2, plus a business coaching service to all successful companies.

In the period 2014-2017, around 26,000 phase 1 and 13,000 phase 2 projects have been submitted to this programme, of which just over 2,100 phase 1 and nearly 700 phase 2 projects have been awarded grants. Spain is the country that has received the most funds under this programme, with €214.5M distributed between 443 phase 1 and 148 phase 2 projects, of the nearly €1,200M awarded so far (19.4% EU).

For the period 2018-2020, the SME Instrument of H2020 takes on a new role as an instrument for SMEs.mbo and is part of the European Innovation Council (EIC) pilot action, with the intention of targeting its support to European SMEs that are able to create new markets from their innovations and offer new value streams to their customers. In order to identify these projects, the SME Instrument assessment based on the written report is complemented, for phase 2 only, by a face-to-face interview with the company in Brussels.

 

New tools of the SME instrument 2018-2020

In view of these new developments in the SME Instrument, the CDTI has developed a set of tools ("SME instrument toolbox") that make it easier for companies to reflect on and fill in the new SME Instrument 2018-2020 templates more accurately.

Although specifically designed for an SME Instrument Phase 2, the results generated by these tools can be used by any company to analyse its market and competition and/or to understand and analyse the variables that condition its scalability.

These new tools offer the following functionalities:

Self-diagnosis of the value proposition

As the European Innovation Council now focuses on market-creating innovations, this will be a variable that will be very present in many of the evaluation criteria. This Excel-based tool allows to analyse the company's value proposition from a market and customer point of view, based on the parameters that define market-creating innovations according to blue ocean strategies.

What's new in the H2020 SME Instrument?
 

Market and competitor analysis

This Excel tool is intended to be a simple guide to the most relevant information that should be documented in the market part of the phase 2 proposals.

What's new in the H2020 SME Instrument?
 

Business and growth model generator

To access H2020's SME Instrument, which seeks to fund companies with scalable and sustainable long-term business models, companies have to explain their business model and growth expectations in their proposals.

This tool integrates several financial models in Excel that allow a projection of the profit and loss of the business in a simple way based on the variables that generate cash or cost.

 

What's new in the H2020 SME Instrument?

CORPORATE FINANCE EXPERTS

Beneficiaries of the H2020 SME Instrument Phase 2

The Spanish companies that have received the most funds in phase 2 of the H2020 SME Instrument are the following:

CompanyDescriptionCountryAmountDate
ZilicoZilico is focused on developing next-generation cancer diagnostics to provide real-time diagnosis of cervical cancer.United Kingdom$19M04.02.2018
Syndesi TherapeuticsSyndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (communication between neurons in the brain).Belgium€17M01.02.2018
FIRE1FIRE1 focuses on developing new remote monitoring devices to improve quality of life and patient outcomes, and reduce healthcare costs.Ireland€40M30.01.2018
EnteromeEnterome Bioscience is a pharmaceutical company developing medicines for chronic medical conditions related to abnormalities in bacterial composition.France€40M04.01.2018
OculisOculis is a private, clinical-stage pharmaceutical development company focused on the development of new ophthalmic medicines.IcelandCHF20M04.01.2018

The distribution of these funds according to sectors of activity is shown below:

What's new in the H2020 SME Instrument?

Other posts that may interest you

http://abra-invest.com/project/sme-instrument-h2020-eic-smeinst-2018-2020/

http://abra-invest.com/beneficiarios-del-programa-de-cdti-feder-innterconecta-2016/

http://abra-invest.com/analisis-cofides-principales-operaciones/

Yes you want to look for investors, buying a company or sell your company, contact our experts in Corporate Finance.

The M&A Professionals

Meet our services

CONTACT US

MEET
OUR
METODOLOGY

Do you want to be up to date?

SUSCRIBE OUR NEWSLETTER

Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?

M&A NEWS
INDUSTRIAL REPORTS
crossmenu